66

Sunny Pharmtech Inc.

6676 · TWO · Healthcare / Biotechnology

7.18TWD+0.16 (+2.28%)

Price History

Full chart

Market Stats

Previous Close7.02
Open7.02
Day Range6.92 – 7.32
52-Week Range10.30 – 19.10
Volume278.40K
Market Cap1.87B
P/E (TTM)0.00
Forward P/E0.00
EPS-2.04
Dividend Yield0.00%
Beta0.29
50-Day Avg11.82
200-Day Avg13.84

About

Sunny Pharmtech Inc. engages in the research, development, and sale of new and generic drug formulations and raw materials in Taiwan, the United States, and internationally. It offers lidocaine ointment that can be used as an anesthetic lubricant for intubation, which temporarily relieves pain associated with minor burns, sunburn, skin abrasions, and insect bites; cyanocobalamin injection for use in vitamin B12 deficiency and pernicious anemia caused by malabsorption; nitrofurantoin capsules for urinary tract infection; and aminocaproic acid tablets for blood diseases and hyper-proteolytic enzymes. It also provides carboprost tromethamine injection for therapeutic abortion and postpartum hemorrhage, as well as Cyclophosphamide injection for malignant diseases. The company was founded in 2014 and is based in Taoyuan City, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Yon-Lian Wu
  • Employees160
  • HeadquartersNo.255, Longyuan 1st Road, Taoyuan City, Taiwan, 325002, Taiwan
  • Websitehttps://www.sunnypharmtech.com

Leadership

  • Dr. Yon-Lian WuFounder, CEO & Chairman
  • Mr. Kun-Hung TsaiCFO & Accounting Supervisor
  • Ms. Yung-Yi ChenVice President of Operations
  • Ms. Lun-Yin ChouVice President of Legal

Financials

Income Statement

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31
Total Revenue234.48M419.94M241.00M359.58M428.83M418.01M
Growth (%)-+79.09%-42.61%+49.21%+19.26%-2.52%
Cost of Revenue139.23M195.87M125.25M152.88M143.30M191.61M
Gross Profit95.25M224.07M115.75M206.71M285.53M226.40M
Gross Margin40.62%53.36%48.03%57.48%66.58%54.16%
Operating Expense309.29M298.41M291.75M394.33M357.62M389.39M
Operating Income-214.04M-74.34M-176.00M-187.62M-72.10M-162.99M
Operating Margin-91.28%-17.70%-73.03%-52.18%-16.81%-38.99%
EBITDA-124.84M10.65M-64.31M-53.96M69.14M-23.91M
EBITDA Margin-53.24%2.54%-26.69%-15.01%16.12%-5.72%
Net Income-226.29M-101.76M-174.79M-170.24M-63.32M-156.00M
Net Income Margin-96.51%-24.23%-72.53%-47.34%-14.77%-37.32%
R&D205.65M182.04M171.37M255.88M208.87M219.28M
R&D as % of Total Revenue87.70%43.35%71.11%71.16%48.71%52.46%
Interest Expense8.28M6.79M5.62M4.59M11.24M9.07M
Interest Expense % of Total Revenue3.53%1.62%2.33%1.28%2.62%2.17%

Balance Sheet

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31
Total Assets1.62B1.50B1.59B1.63B1.71B1.59B
Total Liabilities471.84M455.21M468.26M660.32M512.44M540.68M
Total Equity1.15B1.04B1.13B969.30M1.20B1.05B
Cash294.74M241.72M229.00M222.63M270.56M138.02M
Total Debt390.24M384.62M366.33M562.68M391.43M386.30M
Net Debt95.50M142.90M137.33M340.05M120.87M248.27M

Cash Flow

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31
Operating Cash Flow-117.86M-26.04M-34.35M26.88M38.10M-37.10M
Investing Cash Flow-108.96M-28.59M-213.79M-221.63M-85.85M-85.22M
Financing Cash Flow372.16M1.60M235.43M188.38M95.67M-10.21M
Capital Expenditure78.85M68.83M160.52M195.29M145.20M49.48M
Free Cash Flow-196.72M-94.87M-194.87M-168.41M-107.09M-86.58M
FCF to OCF166.90%364.29%567.28%-626.56%-281.07%233.38%

Key Statistics & Ratios

Market Cap1.87B
Enterprise Value2.08B
Trailing P/E0.00
Forward P/E0.00
Price / Sales8.00
Price / Book2.25
EPS-2.04
Book Value4.83
Revenue (TTM)233.36M
Gross Profit (TTM)36.96M
EBITDA-231.81M
Profit Margin-139.33%
Operating Margin-199.45%
Return on Equity-37.94%
Return on Assets-15.55%
Shares Outstanding169.68M
Shares Float106.09M
Beta0.29
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%